Շվեյցարիա - իտալերեն - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - benralizumabum - soluzione iniettabile - benralizumabum 30 mg, histidinum, histidini hydrochloridum monohydricum, trehalosum dihydricum, polysorbatum 20, aqua ad iniectabile ad solutionem pro 1 ml. - schweres eosinophiles asma - biotechnologika

Շվեյցարիա - իտալերեն - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - olaparibum - compresse rivestite con film - olaparibum 100 mg, copovidonum k 28, silica colloidalis anhydrica, mannitolum, natrii stearylis fumaras corresp. natrium 0.236 mg, Überzug: hypromellosum, macrogolum 400, e 171, e 172 (flavum), pro compresso obducto. - onkologikum - synthetika

Շվեյցարիա - իտալերեն - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - olaparibum - compresse rivestite con film - olaparibum 150 mg, copovidonum k 28, silica colloidalis anhydrica, mannitolum, natrii stearylis fumaras corresp. natrium 0.354 mg, Überzug: hypromellosum, macrogolum 400, e 171, e 172 (flavum), e 172 (nigrum), pro compresso obducto. - onkologikum - synthetika

Շվեյցարիա - իտալերեն - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - ticagrelorum - compresse orodispersibili - ticagrelorum 90 mg, mannitolum, cellulosum microcristallinum, crospovidonum, xylitolum, calcii hydrogenophosphas, natrii stearylis fumaras, hydroxypropylcellulosum, silica colloidalis anhydrica, pro compresso corresp. natrium 0.53 mg. - inibizione piastrinica in combinazione con acido acetilsalicilico - synthetika

Եվրոպական Միություն - իտալերեն - EMA (European Medicines Agency)

astrazeneca ab - andexanet alfa - farmaco effetti collaterali e reazioni avverse - tutti gli altri prodotti terapeutici - per i pazienti adulti trattati con un diretto del fattore xa (fxa), un inibitore (apixaban o rivaroxaban) quando inversione di anticoagulazione è necessario a causa di pericolo di vita o sanguinamento incontrollato.

Շվեյցարիա - իտալերեն - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - benralizumabum - lnjektionslösung - benralizumabum 30 mg, histidinum, histidini hydrochloridum monohydricum, trehalosum dihydricum, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - schweres eosinophiles asma - biotechnologika

Շվեյցարիա - իտալերեն - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - exenatidum - depot-lnjektionssuspension in einem autoinjektor - exenatidum 2 mg, saccharum, poly(lactidum-co-glycolidum) 50/50 (0.40 - 0.49 dl/g), triglycerida media, ad suspensionem pro dosi. - antidiabetico - synthetika

Եվրոպական Միություն - իտալերեն - EMA (European Medicines Agency)

astrazeneca ab - formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - malattia polmonare, ostruttiva cronica - farmaci per le malattie respiratorie ostruttive, - trixeo aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.

Եվրոպական Միություն - իտալերեն - EMA (European Medicines Agency)

astrazeneca ab - acalabrutinib - leucemia, linfocitica, cronica, b-cell - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.

Եվրոպական Միություն - իտալերեն - EMA (European Medicines Agency)

astrazeneca ab - moxetumomab pasudotox - leucemia, hairy cell - agenti antineoplastici - lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (hcl) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (pna).